ChemicalBook > Product Catalog >Biochemical Engineering >Antibody >Disitamab

Disitamab

Disitamab Suppliers list
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 15026964105
Email: 2881489226@qq.com
Company Name: Wuhan Chemstan Biotechnology Co., Ltd.  
Tel: 027-65317797 15926423062
Email: 422450190@qq.com
Company Name: Beijing Jin Ming Biotechnology Co., Ltd.  
Tel: 010-60605840
Email: psaitong@jm-bio.com
Company Name: TargetMol Chemicals Inc.  
Tel: 4008200310 15002144251
Email: marketing@tsbiochem.com
Company Name: Biolab Reagents  
Tel: 027-65279366 18108604356
Email: products@biolabreagent.com
Disitamab Basic information
Product Name:Disitamab
Synonyms:Disitamab;Research Grade Disitamab (DHC09603);Research Grade Disitamab;Disitamab (anti-ERBB2);Immunoglobulin G1, anti-(human tyrosine kinase receptor ErbB2) (human-Mus musculus monoclonal RC48-0 γ1-chain), disulfide with human-Mus musculus monoclonal RC48-0 κ-chain, dimer (ACI)
CAS:2185868-98-6
MF:
MW:0
EINECS:
Product Categories:
Mol File:Mol File
Disitamab Structure
Disitamab Chemical Properties
form Liquid
color Colorless to light yellow
Safety Information
MSDS Information
Disitamab Usage And Synthesis
UsesDisitamab (RC48-0) is a humanized monoclonal antibody targeting HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (Disitamab vedotin (HY-P9985))[1].
in vivo

Disitamab (27 mg/kg; i.v.; once; 5 mL/kg) shows no significant toxicity in monkeys[1].

IC 50HER2
References[1] Jiang J, et al. Preclinical safety profile of disitamab vedotin:a novel anti-HER2 antibody conjugated with MMAE. Toxicol Lett. 2020;324:30-37. DOI:10.1016/j.toxlet.2019.12.027
Disitamab Preparation Products And Raw materials
Tag:Disitamab(2185868-98-6) Related Product Information
Ligufalimab Trevogrumab Vepalimomab Anumigilimab Sudubrilimab Olendalizumab Duvortuxizumab Larcaviximab Immunoglobulin M,anti-(human CD147 (antigen)) (mouse monoclonal ABX-CBL m-chain), disulfide with mousemonoclonal ABX-CBL light chain, pentamer Bertilimumab